参考文献 References
[1] KIM S H, HAN S Y, AZAM T, et al.Interleukin-32: a cytokine and inducer of TNFalpha[J]. Immunity, 2005, 22: 131-142.
[2] NISHIMOTO K P, LAUST A K, NELSON E L.A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32[J]. J Immunol, 2008, 181: 4010-4018.
[3] HEINHUIS B, KOENDERS M I, VAN DEN BERG W B, et al.Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1[J]. J Biol Chem, 2012, 287: 5733-5743.
[4] JAEKAL J, JHUN H, HONG J, et al.Cloning and characterization of bovine interleukin-32 beta isoform [J]. Vet Immunol Immunopathol, 2010, 137: 166-171.
[5] SHODA H, FUJIO K, YAMAGUCHI Y, et al.Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases [J]. Arthritis Res Ther, 2006, 8: R166.
[6] MEGUMI KUDO，EMIKO OGAWA D K, AKANE HARUNA, et al.Oxidative stress induced Interleukin-32 mRNA expression in human bronchial epithelial cells[J]. Respiratory Research, 2012, 13(1), 19.
[7] NETEA M G, AZAM T, LEWIS E C, et al.Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon- gamma- dependent mechanism[J]. PLoS Med, 2006, 3: e277.
[8] KANG J W, CHOI S C, CHO M C, et al. A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10 [J]. Immunology, 2009, 128: e532-540.
[9] SMITH A J, TOLEDO C M, WIETGREFE S W, et al.The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection [J]. J Immunol, 2011, 186: 6576-6584.
[10] HASEGAWA H, THOMAS H J, SCHOOLEY K, et al.Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane- associated protein [J]. Cytokine, 2011, 53: 74-83.
[11] CHEN Q, CARROLL H P, GADINA M.The Newest Interleukins: Recent Additions to the Ever‐Growing Cytokine Family[M].Vitamins and hormones, 2006, 74, 207–228.
[12] GODA C, KANAJI T, KANAJI S, et al.Involvement of IL-32 in activation-induced cell death in T cells[J]. Int Immunol , 2006, 18: 233-240.
[13] AASS K R, KASTNES M H, STANDAL T. Molecular interactions and functions of IL-32[J]. J Leukoc Biol, 2021, 109: 143-159.
[14] NAKAYAMA M, NIKI Y, KAWASAKI T, et al.IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis [J]. Sci Rep, 2013, 3: 2960.
[15] DANIELA NOVICK, MENACHEM RUBINSTEIN, TANIA AZAM, et al. Proteinase 3 is an IL-32 binding protein [J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 103(9), 3316–3321.
[16] ZHANG X, LI L, ZHAO N, et al. A novel role for interleukin 32 in cholestasis[J]. Clin Transl Med, 2021, 11: e594.
[17] OKAMURA A, HARADA K, NIO M, et al.Interleukin-32 production associated with biliary innate immunity and proinflammatory cytokines contributes to the pathogenesis of cholangitis in biliary atresia[J]. Clin Exp Immunol, 2013, 173: 268-275.
[18] ZHANG J, LUO Y, FENG M, et al.Identification of Liver Immune Microenvironment-Related Hub Genes in Liver of Biliary Atresia[J].Frontiers in pediatrics, 2022, 9, 786422.
[19] XU Z, DONG A, FENG Z, et al. Interleukin-32 promotes lipid accumulation through inhibition of cholesterol efflux. Exp Ther Med [J], 2017, 14: 947-952.
[20] DAMEN M, DOS SANTOS J C, HERMSEN R, et al.Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes[J]. Atherosclerosis, 2018, 271: 193-202.
[21] CATALáN V. Increased Interleukin-32 Levels in Obesity Promote Adipose Tissue Inflammation and Extracellular Matrix Remodeling: Effect of Weight Loss[J]. diabetes, 2016, 65(12), 3636–3648.
[22] DALI-YOUCEF N, VIX M, COSTANTINO F, et al.Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance[J]. Hepatol Commun, 2019, 3: 1205-1220.
[23] BASELLI G A, DONGIOVANNI P, RAMETTA R, et al.Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker[J]. Gut, 2020, 69: 1855-1866.
[24] DALI-YOUCEF N, MECILI M, RICCI R, et al.Metabolic inflammation: connecting obesity and insulin resistance[J]. Ann Med, 2013, 45: 242-253.
[25] LEE D H, KIM D H, HWANG C J, et al.Interleukin-32gamma attenuates ethanol-induced liver injury by the inhibition of cytochrome P450 2E1 expression and inflammatory responses [J]. Clin Sci (Lond), 2015, 128: 695-706.
[26] KOURKOUMPETIS T, SOOD G. Pathogenesis of Alcoholic Liver Disease: An Update [J]. Clin Liver Dis, 2019, 23: 71-80.
[27] PAN X, CAO H, LU J, et al.Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB [J]. Mol Immunol, 2011, 48: 1573-1577.
[28] ZOU Y, BAO J, PAN X, et al.NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure[J]. PLoS One , 2015, 10: e0134568.
[29] TIAN Z J, SHEN Y, LI X R, et al.Increased interleukin-32, interleukin-1, and interferon-gamma levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers. J Infect Public Health [J], 2019, 12: 7-12.
[30] KIM D H, PARK E S, LEE A R, et al. Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus [J]. Nat Commun, 2018, 9: 3284.
[31] MOSCHEN A R, FRITZ T, CLOUSTON A D, et al. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis[J]. Hepatology, 2011, 53: 1819-1829.
[32] LIU B, MA X, WANG Q, et al.Marmoset Viral Hepatic Inflammation Induced by Hepatitis C Virus Core Protein via IL-32 [J]. Front Cell Infect Microbiol, 2020, 10: 135.
[33] KO N Y, CHANG S H, LEE J H, et al. Unique expression of a small IL-32 protein in the Jurkat leukemic T cell line[J]. Cytokine, 2008, 42: 121-127.
[34] KANG Y H, PARK M Y, YOON D Y, et al.Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2[J]. Cancer Lett, 2012, 318: 226-233.